Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates. In this episode, experts examine combination ...

Increased specific killing of cancer cells in vitro by the combination of NKX101 and cetuximab, supporting use for combination in solid tumors SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE ...

O'Cearbhaill, MD, of Memorial Sloan Kettering Cancer Center discussed the rationale and early progress of a phase 1/2 ...

Pancreatic cancer research tackles treatment resistance with targeted drug delivery, immune-boosting combinations, and ...